NASDAQ:TPST Tempest Therapeutics Q1 2024 Earnings Report $2.02 -0.13 (-6.05%) Closing price 04:00 PM EasternExtended Trading$2.04 +0.02 (+1.24%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tempest Therapeutics EPS ResultsActual EPS-$4.68Consensus EPS -$5.72Beat/MissBeat by +$1.04One Year Ago EPSN/ATempest Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATempest Therapeutics Announcement DetailsQuarterQ1 2024Date5/9/2024TimeN/AConference Call DateThursday, May 9, 2024Conference Call Time4:00PM ETUpcoming EarningsTempest Therapeutics' Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tempest Therapeutics Earnings HeadlinesTempest Presents Clinical Update at ISCT 2026 Annual MeetingMay 6 at 7:00 AM | globenewswire.comTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingApril 29, 2026 | globenewswire.comThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software stocks two months before they crashed this year. Now, he's warning that one AI lab's breakthrough could CRASH the Nasdaq while igniting a $500 trillion wealth transfer. He's found a little-known $40 "pre-IPO backdoor" into the private startup behind this economic sea change.May 6 at 1:00 AM | Chaikin Analytics (Ad)Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-TApril 22, 2026 | globenewswire.comTempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing EffortsApril 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST)April 1, 2026 | theglobeandmail.comSee More Tempest Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tempest Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tempest Therapeutics and other key companies, straight to your email. Email Address About Tempest TherapeuticsTempest Therapeutics (NASDAQ:TPST) is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies. The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells. Additional preclinical programs aim to block key kinases involved in immune suppression, thereby complementing existing checkpoint inhibitors. Tempest has initiated early‐phase clinical studies in North America and Europe, collaborating with academic and industry partners to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with advanced malignancies. Founded in 2017 and headquartered in Cambridge, Massachusetts, Tempest Therapeutics was established to translate cutting‐edge metabolic and immunological insights into novel oncology treatments. The company’s leadership team combines expertise in drug discovery, clinical development, and regulatory strategy, with decades of experience at both emerging biotechnology firms and large pharmaceutical companies. Tempest is supported by leading life‐science investors and maintains research collaborations to expand its pipeline and accelerate the delivery of new therapies to patients worldwide.View Tempest Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageDigitalOcean’s AI Surge: How Far Can This Rally Go?Years in the Making, AMD’s Upside Movement Has Just BegunCapital One’s Big Bet Faces Rising Credit RiskWestern Digital: The Storage Behemoth Skyrocketing on AI DemandOld Money, New Tech: Western Union's Crypto RebootHow Williams Companies Is Cashing in on the AI Power Boom Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026)W.W. Grainger (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
